RecruitingNot ApplicableNCT04920318

Enhancing Language Function in Primary Progressive Aphasia

Enhancing Language Function in Primary Progressive Aphasia (PPA) With Transcranial Direct Current Stimulation (tDCS)


Sponsor

University of Arizona

Enrollment

20 participants

Start Date

Aug 30, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.


Eligibility

Min Age: 45 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying sham TDCS + language therapy and tDCS + language therapy for people with primary progressive aphasia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 45 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTtDCS + language therapy

In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.

COMBINATION_PRODUCTsham TDCS + language therapy

sham control will be applied with language therapy to the same regions as active TDCS.


Locations(1)

University of Arizona

Tucson, Arizona, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04920318


Related Trials